Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. Loyola University Chicago Stritch School of Medicine, Maywood, IL, United States

Survival: 18.6 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: United States
City/State/Province: Maywood, IL
Hospital: Loyola University Chicago Stritch School of Medicine
Journal: Link
Date: 8/2008

Patients: This phase III study involved 529 women with advanced breast cancer. These patients previously received anthracycline treatment. The median age was 53, ranging from 26 to 83 years of age.

Treatment: Patients were treated with either gemcitabine and paclitaxel or gemcitabine alone. Both gemcitabine and paclitaxel are chemotherapy drugs.

Toxicity: Two patients, one in each treatment group, died from toxicities possibly related to treatment. The toxicities were septicemia (blood infection) and severe asthenia.

Results: The median survival was 18.6 months for patients treated with gemcitabine and paclitaxel, and 15.8 months for those treated with paclitaxel alone.

Support: This study was supported by Eli Lilly, which developed/markets gemcitabine as Gemzar.

Correspondence: Dr. Kathy S. Albain

E-mail to a Friend Email Physician More Information